Prognostic and Predictive Biomarkers in Ovarian Cancers

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03010124

Acronym

OvBIOMark

Enrollment

350

Registered

2017-01-04

Start date

2016-09-26

Completion date

2032-09-01

Last updated

2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

The investigators therefore propose to conduct a biological study of prospectively collected patient tumour samples, ascites, blood and other residual samples (feces, urine, vaginal smear) throughout the disease course where markers (at diagnosis and their change with treatment) will be correlated to outcome in order to investigate how genetic diversity in OC prior to treatment and adaptation following treatment contribute to chemotherapy resistance. In addition freshly collected ascitic samples (and tumour samples) will be subjected to ex vivo DNA repair functional assays and isolated in primary culture (and established as xenografts) for target validation experiments.

Interventions

PROCEDUREBlood sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. New patient with a diagnosis of OC, or 2. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center presenting with progressive disease, and consenting to CT guided biopsy of relapsed disease, or 3. Previously treated patient with frozen or formalin fixed paraffin embedded primary tumour sample available that can be retrieved by the center scheduled for surgery for relapsed disease. 4. Signed informed consent 5. Age ≥ 18 6. Patient affiliated to a social security regimen or beneficiary of the same

Exclusion criteria

1. Patients who do not fit the inclusion criteria and those who refuse an antitumoral treatment; 2. Coagulation abnormalities that contra-indicates the biopsy

Design outcomes

Primary

Measure	Time frame	Description
Progression Free Survival	Correlation of baseline biomarkers with PFS will occur at 12 months following last patient inclusion	up to 12 months

Countries

France

Contacts

CONTACTAlexandra LEARY, MD

alexandra.leary@gustaveroussy.fr+33 (0)1 42 11 43 89

CONTACTDamien DRUBAY

damien.drubay@gustaveroussy.fr+33 (0)1 42 11 42 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026